|
|
|
WELCOME TO DNAVACCINE.COM |
|
A resource for anything and everything related to DNA-mediated immunization with the latest news & articles, a discussion forum, list of events & conferences, and informative emails & free conference pass offerings to registered users. Register and Login to take advantage of the all of the features.
|
|
Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) |
|
Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions.
The immune parameters of HIV/AIDS vaccine candidates that might be relevant in protection against HIV-1 infection are still undefined. The highly attenuated poxvirus strain MVA is one of the most promising vectors to be use as HIV-1 vaccine. We have previously described a recombinant MVA expressing HIV-1 Env, Gag, Pol and Nef antigens from clade B (referred as MVA-B), that induced HIV-1-specific immune responses in different animal models and gene signatures in human dendritic cells (DCs) with immunoregulatory function. |
|
|
Pentagon pulls $1B from WMD-defense efforts to fund vaccine initiative. |
|
The Defense Department has shifted more than $1 billion out of its nuclear, biological and chemical defense programs to underwrite a new White House priority on vaccine development and production to combat disease pandemics, according to government and industry officials.
The planned funding reduction "terminates essential CBRN [chemical, biological, radiological and nuclear] defense programs ... required to meet high priority service needs, prevent casualties and protect against CBRN incidents," according to a Pentagon budget document drafted in early August. |
|
|
Comparative Analysis of Antigen-Targeting Sequences Used in DNA Vaccines. |
|
| Plasmid vectors can be optimized by including specific signals that promote antigen targeting to the major antigen presentation and processing pathways, increasing the immunogenicity and potency of DNA vaccines. A pVAX1-based backbone was used to encode the Green Fluorescence Protein (GFP) reporter gene fused either to ISG (Invariant Surface Glycoprotein) or to TSA (trans-sialidase) Trypanosoma brucei genes. The plasmids were further engineered to carry antigen-targeting sequences, which promote protein transport to the extracellular space (secretion signal), lysosomes (LAMP-1) and to the endoplasmic reticulum (adenovirus e1a) ... |
|
|
Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant. |
|
| Although the critical role of complement component C3d as a molecular adjuvant in preventing virus infection is well established, its role in cancer therapies is unclear. In this study, we have engineered a DNA vaccine that expresses extracellular region of murine VEGFR-2 (FLK1(265-2493)) and 3 copies of C3d (C3d3), a component of complement as a molecular adjuvant, designed to increase antitumor immunity. VEGFR-2 has a more restricted expression on endothelial cells and is upregulated once these cells proliferate during angiogenesis in the tumor vasculature. |
|
|
A novel DNA vaccine constructed by heat shock protein 70 and melanoma antigen-encoding gene 3 against tumorigenesis. |
|
| Melanoma antigen-encoding gene 3 (MAGE-3) is an ideal candidate for a tumor vaccine although its potency need to be increased. Heat shock proteins (HSPs) represents a potential approach for increasing the potency of DNA vaccines. In the present study, a fusion DNA vaccine composed of Mycobacterium tuberculosis HSP70 and MAGE-3 was constructed and used to immunize C57BL/6 mice against B16 or B16-MAGE-3 tumor cells. |
|
|
Memory T cells in Rhesus macaques. |
|
| The Rhesus macaque (Macaca mulatta) is one of the best studied species of Old World monkeys. DNA sequencing of the entire Rhesus macaque genome, completed in 2007, has demonstrated that humans and macaques share about 93% of their nucleotide sequence. Rhesus macaques have been widely used for medical research including drug testing, neurology, behavioral and cognitive science, reproduction, xenotransplantation and genetics. |
|
|
Identifying stabilizers of plasmid DNA for pharmaceutical use. |
|
| To better address the need for developing stable formulations of plasmid DNA-based biopharmaceuticals, 37 compounds from a generally regarded as safe library were examined for their potential use as stabilizers. A plasmid DNA-based therapeutic vaccine, BHT-DNA, was used as a model system. |
|
|
Adjuvant effect of co-stimulatory molecule CD137L on cellular responses to HBsAg DNA vaccination in mice. |
|
| OBJECTIVE: To investigate the adjuvant effect of co-stimulatory molecule CD137L on cellular responses to HBsAg DNA vaccination in mice. |
|
|
Multivalent immunity targeting tumor-associated antigens by intra-lymph node DNA-prime, peptide-boost vaccination. |
|
| Active immunotherapy of cancer has yet to yield effective therapies in the clinic. To evaluate the translatability of DNA-based vaccines we analyzed the profile of T-cell immunity by plasmid vaccination in a murine model, using transcriptome microarray analysis and flow cytometry. DNA vaccination resulted in specific T cells expressing low levels of co-inhibitory molecules (most notably PD-1), strikingly different from the expression profile elicited by peptide immunization. |
|
|
Adjuvant activity of GP96 C-terminal domain towards Her2/neu DNA vaccine is fusion direction-dependent. |
|
| The Her2 is one of tumor-associated antigens (TAA), regarded as an ideal target of immunotherapy. DNA encoding full-length or truncated rat Her2/neu have shown protective and therapeutics potentials against Her2/neu-expressing mammary tumors. However, the efficacy of active vaccination is limited since Her2 is a self-tolerated antigen. Hence, new strategies are required to enhance both the quality and quantity of the immune response against Her2-expressing tumors. |
|
|
DNAVaccine.com Subscribers Receive 10% off BioProcess International Conference & Exhibition registration. |
|
BioProcess International Conference & Exhibition
September 20-24, 2010 : Rhode Island Convention Center : Providence, RI
http://www.ibclifesciences.com/bpi/overview.xml
Get an inside look at the most cutting edge technologies, issues and approaches related to the process development and manufacturing of traditional and novel therapeutic vaccines. View complete details on this session and speakers: http://www.ibclifesciences.com/bpi/vaccine.xml
DNAVaccine.com subscribers, this year THE meeting place for the bioprocessing industry, is also an outstanding forum for those involved in vaccine development and production. An entire day of vaccine programming includes 9 case studies and a plenary session with Pfizer GMS. |
|
|
|
